Search - tctmd.com

Displaying 141 - 160 of 204

Sort: Relevancy | Date

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

News Daily News

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

February 01, 2019

Top News in Heart Failure: 2018

News Features

Top News in Heart Failure: 2018

December 28, 2018

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

August 28, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

News Daily News

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

July 10, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

News Daily News

NSAIDs Account for Large Part of Osteoarthritis-CVD Link, Study Suggests

June 21, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.